Preclinical models seem to suggest that drugs targeting VEGF, FGFR, epidermal growth factor receptor (EGFR), and other signaling pathways can improve the tumor microenvironment and reshape the immune response to inhibit tumor progression (11). The gene discussed is EGFR; the disease is neoplasm.